Related Experiment Video
Updated: May 1, 2026

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets
Published on: September 6, 2019
Pharmacologic prevention of perinatal HIV infection
Natella Y Rakhmanina1, Johannes N van den Anker2
1Division of Infectious Disease, Washington, DC, USA; Division of Pediatric Clinical Pharmacology, Children's National Health System, Washington, DC, USA; Elisabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA; Department of Pediatrics, the George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Abstract:
The goal of antiretroviral therapy for the prevention of mother-to-child transmission (PMTCT) of HIV is to achieve maximal suppression of maternal viral load with minimal maternal, fetal and infant toxicity during pregnancy, delivery and postpartum. In addition to the efficacy and toxicity of antiretroviral therapy, the consideration of HIV resistance in mothers and infected newborns further complicates therapeutic choices for PMTCT. This manuscript summarizes current approaches to PMTC in diverse international settings.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retrovirus Life Cycles
Sexually Transmitted Infections
Rh Blood Group
Inhibitors of Viral Protein Synthesis
Cytomegalovirus Disease

